Browse studies

Find your next paid study

6 recruiting studies matching your filters

Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)

This Phase I study will evaluate the safety of autologous Epstein-Barr virus-specific T lymphocytes modified to express a constitutively active IL7 receptor (C…

Diffuse Large B-Cell Lymphoma (DLBCL)Hodgkin LymphomaPeripheral T-cell Lymphoma (PTCL)+2 more

Estimated

~$150 – $3,000

Actual pay is set by the research site.

The Methodist Hospital Research InstituteNCT07729397

Phase 1

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients wit…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+5 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Nurix Therapeutics, Inc.NCT04830137

Phase 2

ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL

Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Iden…

Diffuse Large B-Cell Lymphoma (DLBCL)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Danielle WallaceNCT06828991

Phase 3

A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused…

Diffuse Large B-cell Lymphoma (DLBCL)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Regeneron PharmaceuticalsNCT06091865

Phase 2

Epcoritamab in Combination With R-CHOP Debulking in Newly Diagnosed Patients With Aggressive Non-Hodgkin Lymphoma (DLBCL)

A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggress…

Non-Hodgkin's B-cell LymphomaLymphoma Non-HodgkinDiffuse Large B-Cell Lymphoma (DLBCL)

Estimated

~$75 – $3,000

Actual pay is set by the research site.

Carrie Ho, MDNCT07588698

Phase 2

A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial

This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse…

Diffuse Large B-cell Lymphoma (DLBCL)CardiotoxicityLymphoma

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Beth Israel Deaconess Medical CenterNCT07654426